<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40252">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01993823</url>
  </required_header>
  <id_info>
    <org_study_id>G238OTIII/11IA01</org_study_id>
    <nct_id>NCT01993823</nct_id>
  </id_info>
  <brief_title>Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Salvat</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Salvat</source>
  <oversight_info>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of G238 for the treatment
      of otomycosis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical and mycological evaluation</measure>
    <time_frame>Day 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Efficacy will be assessed primarily by evaluation of the fungal culture, and the sum of signs and symptom scores (pruritus, otalgia, otorrhea and aural fullness obstruction to be scored as 0=absent; 1= mild; 2=moderate; 3=severe). The primary efficacy variable is the proportion of subjects with a negative culture for fungus, AND a signs and symptom score of &quot;0&quot; on Day 24.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in signs/ symptoms</measure>
    <time_frame>2 weeks and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>The secondary efficacy variables will include:
Proportion of subjects with signs and symptoms score of &quot;0&quot; at each visit.
Proportion of subjects with a negative culture for fungus or presumed eradication on Day 24.
The changes in signs and symptoms after two (2) weeks of treatment.
The changes in signs/symptoms at Day 24.
The mycological study results obtained in the cultures at day 24.
The number of patients with clinical cure or improvement at day 14 and 24.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Mycological study</measure>
    <time_frame>Day 24</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Otomycosis</condition>
  <arm_group>
    <arm_group_label>G238</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five drops into the ear canal twice daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clotrimazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Five drops into the ear canal twice daily for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G238</intervention_name>
    <description>Five drops into the ear canal twice daily for 14 days</description>
    <arm_group_label>G238</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clotrimazole</intervention_name>
    <description>Five drops into the ear canal twice daily for 14 days</description>
    <arm_group_label>Clotrimazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older.

          -  Clinical diagnosis of otomycosis where topical treatment is indicated.

        Exclusion Criteria:

          -  Other ear diseases.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enrique Jimenez, MD</last_name>
    <phone>+34933946400</phone>
    <phone_ext>470</phone_ext>
    <email>clinicaltrials@salvatbiotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Laboratorios SALVAT, S.A.</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Jimenez, MD</last_name>
      <phone>+34933946400</phone>
      <phone_ext>470</phone_ext>
      <email>clinicaltrials@salvatbiotech.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 20, 2013</lastchanged_date>
  <firstreceived_date>October 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clotrimazole</mesh_term>
    <mesh_term>Miconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
